Wohns R N, Colpitts M, Clement T, Karuza A, Blackett W B, Foutch R, Larson E
Am J Med. 1986 Jan;80(1):32-6. doi: 10.1016/0002-9343(86)90045-8.
Twenty-one climbers who were members of the American Ultima Thule Everest Expedition participated in a double-blind, randomized clinical trial of phenytoin prophylaxis for acute mountain sickness during the approach to the northeast ridge of Mount Everest. The study was carried out between Beijing and base camp at 16,800 feet. Time spent ascending from Beijing to base camp averaged 13 days. High-altitude symptom questionnaires were filled out beginning in Lhasa at 11,800 feet and in Xigatse at 12,000 feet, in Xegar at 14,000 feet, and at base camp. Computer analysis of the questionnaire answers performed by an impartial analyst revealed that climbers who took phenytoin were less likely to have headaches at base camp. No other statistically significant differences were observed, but the power of the sample size was low.
21名美国终极图勒珠峰探险队的登山队员参与了一项双盲、随机临床试验，该试验旨在研究在前往珠穆朗玛峰东北山脊途中使用苯妥英预防急性高山病的效果。研究在北京和海拔16,800英尺的大本营之间进行。从北京到大本营的攀登时间平均为13天。从拉萨（海拔11,800英尺）、日喀则（海拔12,000英尺）、协格尔（海拔14,000英尺）以及大本营开始，队员们填写了高原症状问卷。由一名公正的分析师对问卷答案进行的计算机分析显示，服用苯妥英的登山队员在大本营出现头痛的可能性较小。未观察到其他具有统计学意义的差异，但样本量的检验效能较低。
